• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    34162178.pdf
    Size:
    1.253Mb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Evens, A. M.
    Connors, J. M.
    Younes, A.
    Ansell, S. M.
    Kim, W. S.
    Radford, John A
    Feldman, T.
    Tuscano, J.
    Savage, K. J.
    Oki, Y.
    Grigg, A.
    Pocock, C.
    Dlugosz-Danecka, M.
    Fenton, K.
    Forero-Torres, A.
    Liu, R.
    Jolin, H.
    Gautam, A
    Gallamini, A.
    Show allShow less
    Affiliation
    Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Effective and tolerable treatments are needed for older patients with classical Hodgkin lymphoma (cHL). We report results for older patients with cHL treated in the large phase III ECHELON-1 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Modified progression-free survival (PFS) per independent review facility (IRF) for older versus younger patients (aged ≥60 versus.
    Citation
    Evens AM, Connors JM, Younes A, Ansell SM, Kim WS, Radford J, et al. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. haematol . 2021 Jun 24.
    Journal
    Haematologica
    URI
    http://hdl.handle.net/10541/624232
    DOI
    10.3324/haematol.2021.278438
    PubMed ID
    34162178
    Additional Links
    https://dx.doi.org/10.3324/haematol.2021.278438
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.3324/haematol.2021.278438
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
    • Authors: Straus DJ, Długosz-Danecka M, Connors JM, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Munoz J, Lee HJ, Kim WS, Advani R, Ansell SM, Younes A, Gallamini A, Liu R, Little M, Fenton K, Fanale M, Radford J
    • Issue date: 2021 Jun
    • Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.
    • Authors: Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ
    • Issue date: 2019 Mar 15
    • Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
    • Authors: Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J, ECHELON-1 Study Group
    • Issue date: 2018 Jan 25
    • Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
    • Authors: Straus DJ, Długosz-Danecka M, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Connors JM, Radford J, Munoz J, Kim WS, Advani R, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero-Torres A, Gallamini A
    • Issue date: 2020 Mar 5
    • Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
    • Authors: Ansell SM, Radford J, Connors JM, Długosz-Danecka M, Kim WS, Gallamini A, Ramchandren R, Friedberg JW, Advani R, Hutchings M, Evens AM, Smolewski P, Savage KJ, Bartlett NL, Eom HS, Abramson JS, Dong C, Campana F, Fenton K, Puhlmann M, Straus DJ, ECHELON-1 Study Group
    • Issue date: 2022 Jul 28
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.